← Veradermics, Inc (MANE) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Veradermics, Inc (MANE)
Pharmaceutical Preparations · market cap $4.8B · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-10 (est.)
Earnings
Pipeline
3
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Veradermics, Inc. (MANE) is a clinical-stage pharmaceutical company focused on dermatology, trading at ~$110 per share with a ~$4.6B market cap. Its lead asset VDPHL01 is in Phase 3 for Androgenetic Alopecia (AGA), with a pivotal readout expected December 2026 and a once-daily formulation (VDPHL01 QD) Phase 3 readout expected mid-2027. The company holds $168.4M in cash, providing roughly 24 months of runway.
The catalyst path
- 2026-11-10 (est.)Earningsimp 5/10
- 2026-12-15 (est.)Phase 3 · VDPHL01imp 9/10
- 2027-06-15 (est.)Phase 3 · VDPHL01 QDimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| VDPHL01 | Phase 3 | Androgenetic Alopecia |
| VDPHL01 QD | Phase 3 | Androgenetic Alopecia (AGA) |
| VDMN-21 Patch Low Dose | Phase 2 | Verruca Vulgaris |
Price & technical context
3-month
-9.7%
6-month
+99.4%
12-month
—
52-wk range
$37.03–$129.74
vs 50-day MA
+9.2%
vs 200-day MA
—
Realized vol
86.0%
Max drawdown
-24.8%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MANE (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.